Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

| CORCEPT THERAPEUTICS IN Form 4 February 10, 2014 | ĨĊ | | | | | |
|---|---|--|--|--|--|--|
| FORM 4 UNITED ST | | | OMB APPROVAL | | | |
| UNITED ST | ON OMB Number: 3235-0287 | | | | | |
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction | Estimated average burden hours per response 0.5 34, | | | | | |
| 1(b). | 30(h) of the Investment Compar | | | | | |
| (Print or Type Responses) | | | | | | |
| 1. Name and Address of Reporting Pers LeDoux Anne M | son [*] 2. Issuer Name and Ticker or Symbol CORCEPT THERAPEU' [CORT] | Issuer TICS INC | ip of Reporting Person(s) to Check all applicable) | | | |
| (Last) (First) (Midd C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE | lle) 3. Date of Earliest Transaction (Month/Day/Year) 02/06/2014 | Director X Officer below) | r (give title 10% Owner (give title Other (specify below) VP & Controller | | | |
| (Street) | 4. If Amendment, Date Origina Filed(Month/Day/Year) | Applicable Lin _X_ Form filed | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person | | | |
| MENLO PARK, CA 94025 | | Form filed Person | by More than One Reporting | | | |
| (City) (State) (Zip |) Table I - Non-Derivative | Securities Acquired, Dispos | ed of, or Beneficially Owned | | | |
| (Instr. 3) any | . Deemed 3. 4. Securit ecution Date, if TransactionAcquired | ies 5. Amount of (A) or Securities of (D) Beneficially | 6. Ownership Form: Direct (D) or Indirect (I) (I) (Instr. 4) 7. Nature of Indirect Beneficial (I) (Instr. 4) | | | |
| Reminder: Report on a separate line for | each class of securities beneficially ow | ned directly or indirectly. | | | | |

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | | 4. Transactio Code (Instr. 8) | 5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | Expiration Date Underly | | 7. Title and A Underlying S (Instr. 3 and | Securities D | | | |
|--|---|---|-------------------|--|--|-------------------------|--------------------|---|-------------------------------------|--|--|--|
| | | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| Stock option (right to buy) | \$ 3.02 | 02/06/2014 | | А | 60,000 | <u>(1)</u> | 02/06/2024 | Common Stock | 60,000 | | | |
| Reporting Owners | | | | | | | | | | | | |
| Reporting Owner Name / Address | | | | | ps | | | | | | | |
| кероги | ng Owner Na | | Director 10% Owne | er Officei | r | Other | | | | | | |
| 149 COM | CEPT THE | ERAPEUTICS LTH DRIVE 94025 | | VP & | controller | | | | | | | |
| Signa | tures | | | | | | | | | | | |
| /s/ Joseph K. Belanoff, CEO of Corcept Therapeutics Incorporated, attorney-in-fact | | | | | ed, | (|)2/10/2014 | | | | | |
| **Signature of Reporting Person | | | | | | Date | | | | | | |

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Exercisable with respect to 2.08334% of the total number of Option Shares on the monthly anniversary of 2/6/2014 and each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.